Skip to main content

Verdicts against Meta, YouTube validate concerns long raised by parents, child safety advocates

For years, parents, teenagers, pediatricians, educators and whistleblowers have pushed the idea that social media is detrimental to young people’s mental health and can lead to addiction, eating disorders, sexual exploitation and suicide.

For the first time, juries in two states took their side.

In Los Angeles on Wednesday, a jury found both Meta and YouTube liable for harms to children using their services. In New Mexico, a jury determined that Meta knowingly harmed children’s mental health and concealed what it knew about child sexual exploitation on its platforms.

Tech watchdog groups, families and children’s advocates cheered the jury decisions.

“The era of Big Tech invincibility is over,” said Sacha Haworth, executive director of The Tech Oversight Project. “After years of gaslighting from companies like Google and Meta, new evidence and testimony have pulled back the curtain and validated the harms young people and parents have been telling the world about for years.”

While it’s too soon to tell if this week’s outcomes will lead to fundamental changes in how social media platforms treat their young users, the dual verdicts signal a changing tide of public perception against tech companies that is likely to lead to more lawsuits and regulation. For years, they have argued that the harms their platforms cause to children are a mere byproduct, unintentional and inevitable consequences of broader societal issues or bad actors taking advantage of safeguards. They pushed against the notion that psychological harms could be the result of social media use and downplayed research that showed otherwise.

When asked about whether people tend to use a platform or product more if it’s addictive during his testimony in the Los Angeles trial, Meta CEO Mark Zuckerberg said “I’m not sure what to say to that. I don’t think that applies here.”

The verdicts show the public’s growing willingness to hold the companies responsible for harms and demand meaningful changes in how they operate. What’s not apparent, at least not yet, is whether the companies will take heed. Both Meta and Google said they disagree with the verdicts and are exploring legal options, including appeals.

Arturo Béjar, a former Meta engineering director who raised alarms about Instagram’s harms inside the company for years before testifying in Congress in 2023, said jury trials “level the playing field” for these trillion-dollar companies. But he cautioned that it will take actual regulation to rein them in.

“One thing that I saw working inside the company that effectively led to behavior change was when an attorney general or the FTC stepped in and required things of the company,” he said. “Both New Mexico and Los Angeles and all the attorneys general that are part of this process have really an extraordinary opportunity and the ability to ask for meaningful change.”

While both cases focused on harms to children, there are key differences between the two. New Mexico’s lawsuit was filed by state Attorney General Raúl Torrez in 2023. State investigators built their case by posing as children on social media, then documenting sexual solicitations they received as well as Meta’s response. The jury was asked to determine if Meta violated New Mexico’s consumer protection law.

The Los Angeles case had a single plaintiff, who goes by the initials KGM, against Meta, Google’s YouTube, TikTok and Snap. TikTok and Snap settled before trial. The plaintiff in this case argued that the platform design features of the two remaining defendants, Meta and YouTube, were designed to be addictive, especially for young users. Because thousands of families have filed similar lawsuits, KGM and a handful of other plaintiffs have been selected for bellwether trials — essentially test cases for both sides to see how their arguments play out before a jury, eventually leading to a broader settlement reminiscent of the Big Tobacco and opioid trials.

By focusing on deliberate design choices and product liability, the lawsuits were able to sidestep Section 230, which generally exempts internet companies from liability for the material users post on their services. Past lawsuits, which have focused on how the platforms distributed content, often failed on these grounds.

“For the first time, courts have held social media platforms accountable for how their product design can harm users,” said Nikolas Guggenberger, an assistant professor of law at the University of Houston Law Center. “This is a new legal territory that could reshape an industry long shielded by Section 230. Platforms will have to rethink their focus on engagement at any cost, which has outlived itself.”

The final outcome of the cases could take years to resolve pending appeals and settlement agreements, but experts say the shift in the public’s sentiment and understanding of social media’s dangers is already happening. In a 2025 Pew Research Center poll, for instance, 48% of teens said social media harms people their age. In 2022, only 32% said the same.

Amid social media’s reckoning, however, artificial intelligence chatbots are emerging as the next frontier in the fight to make technology safer for young people.

“You can ban today’s harm, but how do you know what tomorrow is going to bring?” said Sarah Kreps, a professor and director of Cornell University’s Tech Policy Institute. Whether it’s another social media app, AI or some other new technology, she added, new things will crop up.

“And people will flock to those because where there’s demand you will see a supply come to meet that demand,” she said.

When you have advanced prostate cancer: What living with the disease looks like

(CNN) — “How long do I have to live ?”When I tell a patient he has prostate cancer, this is usually what he asks me first.With early-stage or low-grade prostate cancer, I can offer strong reassurance: Your life expectancy is good — expect a five-year relative survival rate of greater than 99% with treatment. Simply put, most men will not die from low-grade prostate cancer.However, once the cancer has spread outside the prostate to the bones and other organs the answer becomes more difficult. Treatment has changed dramatically over the past decade for advanced prostate cancer. New drugs, better imaging and the earlier use of combined therapies are helping men live longer.In a video released July 15, former President Joe Biden gave an update on his prostate cancer, saying he was receiving treatments that have been going well. In May 2025, Biden officially announced that he had an aggressive form of prostate cancer that had spread to his bones. Since then, based on official updates, he has continued hormone therapy, completed a course of radiation and maintained a public presence.His diagnosis brought renewed attention to prostate cancer screening and treatment. Now, more than a year later, his cancer journey offers an opportunity to examine what has changed in the treatment of advanced prostate cancer — and the hope these offer men living with the disease.I recently saw a patient who was diagnosed three years ago with cancer that had already spread to multiple areas in his bones. Since then, he has taken cruises, traveled with his family and spent weekends babysitting his grandchildren.He gets tired and cannot garden the way he once did. But he is still alive and considers every day a blessing. His experience, and what we see with Biden, shows what living with metastatic prostate cancer can look like today.Understanding survival ratesIf they haven’t asked their doctor already, many patients go online and find five-year survival rates, but every number they may find online comes with a huge asterisk.The American Cancer Society reports five-year relative survival of greater than 99% when prostate cancer is found in or near the prostate. The figure drops to 38% when it has reached distant parts of the body.But that number is based on large groups of men treated years ago. It does not fully reflect the impact of newer treatments — or account for an individual man’s age, overall health and response to therapy.Survival statistics describe groups of patients but do not predict what will happen to one person. That is why the 38% figure cannot tell us how long Biden — or any individual patient — will live. These patients’ outlook depends on details of their cancer and how they are responding to treatments.It’s treated more aggressively nowA man diagnosed with metastatic prostate cancer a decade ago and a man diagnosed today would not receive the same treatment. The thinking now is to use our best treatments early instead of holding back.For years, doctors began with hormone therapy — usually injections that lower testosterone — and saved other treatments until the cancer stopped responding.Today, those injections are often combined from the start with a newer hormone-blocking drug and/or chemotherapy. These combinations have helped men live longer and are one of the biggest shifts of the past decade.What Biden’s diagnosis told usThere are three details about Biden’s cancer that help doctors like me understand how aggressive it is and how to manage it effectively. Official statements highlighted that his cancer had a Gleason score of 9. The cancer had spread to his bones, and it was labeled as hormone-sensitive.The Gleason score is assigned after a pathologist examines biopsy samples. Scores typically range from 6 to 10, with higher numbers indicating more aggressive cancer. A score of 9 falls into the most aggressive category. However, the score alone cannot tell us whether the cancer has spread outside the prostate.When prostate cancer spreads, the most common destination is the bones — particularly the spine, pelvis and ribs. It can also reach organs such as the lungs or liver. Once it has reached distant parts of the body, it is generally not curable, but treatment can put a brake on it for years.Prostate cancer can also be hormone-sensitive or hormone-resistant. Because it typically relies on testosterone to grow, lowering the hormone or blocking its effects can help control the cancer. Hormone-sensitive means it still responds to these treatments.Over time, most advanced or metastatic prostate cancers find ways to grow despite low testosterone levels, which mean they are now hormone-resistant. Lowering testosterone alone is no longer enough to control the cancer, so doctors have to turn to additional therapies.Knowing if the cancer has spreadThe most sensitive imaging test available today is a PSMA PET scan. It uses a radioactive tracer that seeks out a protein found on the surface of prostate cancer cells. Areas containing cancer may appear as bright spots, helping identify where the cancer has spread. The American Urological Association supports using this imaging test to determine whether high-risk prostate cancer has spread and to help establish its stage.A traditional bone scan, used for decades, highlights areas where bone is reacting to injury or disease. It remains an alternative imaging option, but PSMA PET is increasingly replacing its use.What areas light up and where matter when deciding on treatments. A single spot in the spine and cancer that has spread to the liver are both called stage 4, but they are not the same disease and may not be treated the same way.Doctors also consider how much cancer has spread. We label it as “low-volume” disease when the cancer has reached a limited number of areas. High volume is when the spread is more widespread or has reached other organs such as the liver or lungs.Both require treatment that works throughout the body. Treatment for metastatic disease generally includes therapy that works throughout the body. For men with low-volume disease, adding radiation to the prostate may also help them live longer.Biden has completed a course of radiation, but his team has not disclosed what area was treated or enough detail to determine whether his cancer would be considered low- or high-volume.Treatment has become more preciseBeyond starting more treatments earlier, doctors can increasingly tailor therapy to the biology of an individual man’s cancer. We can now test both the tumor and a patient’s own DNA for mutations that help guide treatment.Roughly 1 in 10 men with metastatic prostate cancer carries an inherited mutation affecting the body’s ability to repair DNA. The best known are BRCA1 and BRCA2, the same genes linked to some breast and ovarian cancers.Certain mutations found in the tumor or inherited DNA may make targeted drugs called PARP inhibitors an option. If a mutation is inherited, it also gives family members information they can act on through genetic counseling, testing and earlier screening.Another advance is radioligand therapy. If a scan shows that cancer cells carry a protein called PSMA, doctors can attach radiation to a molecule that seeks out that protein. Delivered through an IV, it targets cancer cells throughout the body. This approach was expanded last year to more men whose cancer had become hormone resistant.Living longer can come with costsEvery treatment can cause side effects. With hormone therapy, one of the first is often hot flashes, similar to what women experience during menopause. These are not dangerous, but they can affect a man’s quality of life.Fatigue is also common. Testosterone helps maintain muscle, so lowering it can reduce strength and energy. Regular walking and resistance training can help preserve muscle and reduce fatigue.The side effect almost no one talks about is loss of sex drive or low libido. At diagnosis, most men are thinking about staying alive, not their libido. But months later, it often matters. It is worth discussing with your care team and your partner rather than assuming it is simply the price of treatment.The side effect I worry about most is weaker bones. Low testosterone reduces bone density, while cancer deposits can weaken the bone’s structure. Follow-up care should include exercise, a bone-density scan, and ensuring adequate levels of calcium and vitamin D. For men with hormone-resistant cancer that has spread to bone, bone-protecting drugs can reduce the risk of fractures and other complications.New or worsening back pain, especially with leg weakness, numbness or trouble controlling the bladder or bowels? These could mean the cancer is pressing on the spinal cord. It is a true medical emergency that requires immediate attention.Cancer care requires a team approachIdeally, several doctors work together to coordinate a patient’s care. The urologist is often the starting point. A medical oncologist manages treatments that work throughout the body, while a radiation oncologist targets specific areas, whether that is the prostate itself or a painful bone lesion. The primary care doctor helps protect the patient’s heart and bones and looks after the person’s overall health.A man’s age, other medical conditions, ability to tolerate side effects and goals for treatment all shape treatment plans. Two men with nearly identical test results may be offered — or choose — different paths based on their health and priorities.Good communication among doctors is essential, but gaps can happen. Being your own advocate means knowing who is on your care team, asking questions and understanding your options.I also recommend bringing someone you trust to important visits for support and to take notes and help you remember what was discussed.More treatments, better testing offer hopeFor men worried about prostate cancer, talk with your health care provider about the benefits and risks of PSA testing. Black men and those with a strong family history should begin that conversation in their 40s. New urinary symptoms are often not cancer, but they still deserve attention, as does blood in the urine or semen, unexplained weight loss and/or persistent back or bone pain.For men living with advanced prostate cancer, there is reason for hope. There are more treatments and better testing than there were a decade ago, and good care pays attention to how a man feels, not just to what his scans show.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
Read Next Story